Correction to: Role of Hippo pathway dysregulation from gastrointestinal premalignant lesions to cancer

Affiliations

¹ Clinical Trial Center, Biostatistics and Bioinformatics Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
² SAFU Laboratory, Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
³ Pathology Unit, Mediterranean Institute of Oncology, Viagrande, Italy.
⁴ Medical Oncology Unit, Mediterranean Institute of Oncology, Viagrande, Italy.
⁵ Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy.
⁶ Translational Oncology Research Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
⁷ Scientific Directorate, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
⁸ Cellular Network and Molecular Therapeutic Target Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy. giulia.bon@ifo.it.
⁹ Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Published Erratum

Giulia Schiavoni et al. J Transl Med. 2024.

. 2024 May 3;22(1):420.

doi: 10.1186/s12967-024-05161-3.

¹ Clinical Trial Center, Biostatistics and Bioinformatics Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
² SAFU Laboratory, Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
³ Pathology Unit, Mediterranean Institute of Oncology, Viagrande, Italy.
⁴ Medical Oncology Unit, Mediterranean Institute of Oncology, Viagrande, Italy.
⁵ Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy.
⁶ Translational Oncology Research Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
⁷ Scientific Directorate, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
⁸ Cellular Network and Molecular Therapeutic Target Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy. giulia.bon@ifo.it.
⁹ Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

No abstract available

Erratum for

Role of Hippo pathway dysregulation from gastrointestinal premalignant lesions to cancer.
Schiavoni G, Messina B, Scalera S, Memeo L, Colarossi C, Mare M, Blandino G, Ciliberto G, Bon G, Maugeri-Saccà M. Schiavoni G, et al. J Transl Med. 2024 Feb 29;22(1):213. doi: 10.1186/s12967-024-05027-8. J Transl Med. 2024. PMID: 38424512 Free PMC article. Review.

1. Schiavoni et al. (2024) Role of Hippo pathway dysregulation from gastrointestinal premalignant lesions to cancer (2024). 22:213 10.1186/s12967-024-05027-8. - PMC - PubMed